BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 36437392)

  • 21. Success of referral to genetic counseling after positive lynch syndrome screening test.
    Irons RF; Contino KM; Horte JJ; Levin B; Mattie KD; Wight M; Kwiatt ME; Behling KC; Edmonston TB; McClane SJ
    Int J Colorectal Dis; 2017 Sep; 32(9):1345-1348. PubMed ID: 28664346
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tumor mutational signatures in sebaceous skin lesions from individuals with Lynch syndrome.
    Georgeson P; Walsh MD; Clendenning M; Daneshvar S; Pope BJ; Mahmood K; Joo JE; Jayasekara H; Jenkins MA; Winship IM; Buchanan DD
    Mol Genet Genomic Med; 2019 Jul; 7(7):e00781. PubMed ID: 31162827
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Universal screening for Lynch syndrome in endometrial cancers: frequency of germline mutations and identification of patients with Lynch-like syndrome.
    Dillon JL; Gonzalez JL; DeMars L; Bloch KJ; Tafe LJ
    Hum Pathol; 2017 Dec; 70():121-128. PubMed ID: 29107668
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Maximizing cancer prevention through genetic navigation for Lynch syndrome detection in women with newly diagnosed endometrial and nonserous/nonmucinous epithelial ovarian cancer.
    Kim SR; Tone A; Kim RH; Cesari M; Clarke BA; Eiriksson L; Hart TL; Aronson M; Holter S; Lytwyn A; Maganti M; Oldfield L; Gallinger S; Bernardini MQ; Oza AM; Djordjevic B; Lerner-Ellis J; Van de Laar E; Vicus D; Pugh TJ; Pollett A; Ferguson SE
    Cancer; 2021 Sep; 127(17):3082-3091. PubMed ID: 33983630
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Performance characteristics of screening strategies for Lynch syndrome in unselected women with newly diagnosed endometrial cancer who have undergone universal germline mutation testing.
    Ferguson SE; Aronson M; Pollett A; Eiriksson LR; Oza AM; Gallinger S; Lerner-Ellis J; Alvandi Z; Bernardini MQ; MacKay HJ; Mojtahedi G; Tone AA; Massey C; Clarke BA
    Cancer; 2014 Dec; 120(24):3932-9. PubMed ID: 25081409
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prevalence and molecular characteristics of DNA mismatch repair protein-deficient sebaceous neoplasms and keratoacanthomas in a Japanese hospital-based population.
    Kuwabara K; Suzuki O; Chika N; Kumamoto K; Minabe T; Fukuda T; Arai E; Tamaru JI; Akagi K; Eguchi H; Okazaki Y; Ishida H
    Jpn J Clin Oncol; 2018 Jun; 48(6):514-521. PubMed ID: 29718441
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of universal screening in major lynch-associated tumors: a systematic review of literature.
    Kunnackal John G; Das Villgran V; Caufield-Noll C; Giardiello FM
    Fam Cancer; 2022 Jan; 21(1):57-67. PubMed ID: 33426601
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Discordant Mismatch Repair Protein Immunoreactivity in Lynch Syndrome-Associated Neoplasms:  A Recommendation for Screening Synchronous/Metachronous Neoplasms.
    Roth RM; Haraldsdottir S; Hampel H; Arnold CA; Frankel WL
    Am J Clin Pathol; 2016 Jul; 146(1):50-6. PubMed ID: 27357288
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Challenges in the diagnosis and management of Lynch Syndrome in an Indigenous family living in a remote West Australian community.
    Schofield L; Goldblatt J; Iacopetta B
    Rural Remote Health; 2011; 11(4):1836. PubMed ID: 22188021
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The proportion of endometrial tumours associated with Lynch syndrome (PETALS): A prospective cross-sectional study.
    Ryan NAJ; McMahon R; Tobi S; Snowsill T; Esquibel S; Wallace AJ; Bunstone S; Bowers N; Mosneag IE; Kitson SJ; O'Flynn H; Ramchander NC; Sivalingam VN; Frayling IM; Bolton J; McVey RJ; Evans DG; Crosbie EJ
    PLoS Med; 2020 Sep; 17(9):e1003263. PubMed ID: 32941469
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Is tumor testing efficiency for Lynch syndrome different in rectal and colon cancer?
    Marabelli M; Gandini S; Rafaniello PR; Calvello M; Tolva G; Feroce I; Lazzeroni M; Marino E; Dal Molin M; Trovato C; Guerrieri-Gonzaga A; Petz WL; Barberis M; Bertario L; Bonanni B
    Dig Liver Dis; 2020 Dec; 52(12):1503-1511. PubMed ID: 32620519
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Systematic immunohistochemistry screening for Lynch syndrome in early age-of-onset colorectal cancer patients undergoing surgical resection.
    Steinhagen E; Shia J; Markowitz AJ; Stadler ZK; Salo-Mullen EE; Zheng J; Lee-Kong SA; Nash GM; Offit K; Guillem JG
    J Am Coll Surg; 2012 Jan; 214(1):61-7. PubMed ID: 22192923
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Somatic tumor testing implications for Lynch syndrome germline genetic testing.
    Barrus K; Purington N; Chun N; Ladabaum U; Ford JM
    Cancer Genet; 2022 Jun; 264-265():16-22. PubMed ID: 35286930
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lessons learnt from the implementation of a colorectal cancer screening programme for lynch syndrome in a tertiary public hospital.
    Dueñas N; Navarro M; Sanjuán X; Ruiz N; Iglesias S; Matias-Guiu X; Guardiola J; Kreisler E; Biondo S; González S; Legido R; Blanco A; Navarro S; Asiain L; Santos C; Capellá G; Pineda M; Brunet J
    Cancer Epidemiol; 2023 Feb; 82():102291. PubMed ID: 36410089
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Scoping the family history: assessment of Lynch syndrome (hereditary nonpolyposis colorectal cancer) in primary care settings--a primer for nurse practitioners.
    Maradiegue A; Jasperson K; Edwards QT; Lowstuter K; Weitzel J
    J Am Acad Nurse Pract; 2008 Feb; 20(2):76-84. PubMed ID: 18271762
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of novel pathogenic MSH2 mutation and new DNA repair genes variants: investigation of a Tunisian Lynch syndrome family with discordant twins.
    Jaballah-Gabteni A; Tounsi H; Kabbage M; Hamdi Y; Elouej S; Ben Ayed I; Medhioub M; Mahmoudi M; Dallali H; Yaiche H; Ben Jemii N; Maaloul A; Mezghani N; Abdelhak S; Hamzaoui L; Azzouz M; Boubaker S
    J Transl Med; 2019 Jun; 17(1):212. PubMed ID: 31248416
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of universal immunohistochemical screening of sebaceous neoplasms in a service setting.
    Schon K; Rytina E; Drummond J; Simmonds J; Abbs S; Sandford R; Tischkowitz M
    Clin Exp Dermatol; 2018 Jun; 43(4):410-415. PubMed ID: 29333623
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Germline Testing of Mismatch Repair Genes Is Needed in the Initial Evaluation of Patients With Muir-Torre Syndrome-Associated Cutaneous Sebaceous Neoplasms: A Case Series.
    Cohen PR; Kurzrock R
    Cureus; 2023 Jan; 15(1):e33975. PubMed ID: 36824550
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The histomorphology of Lynch syndrome-associated ovarian carcinomas: toward a subtype-specific screening strategy.
    Chui MH; Ryan P; Radigan J; Ferguson SE; Pollett A; Aronson M; Semotiuk K; Holter S; Sy K; Kwon JS; Soma A; Singh N; Gallinger S; Shaw P; Arseneau J; Foulkes WD; Gilks CB; Clarke BA
    Am J Surg Pathol; 2014 Sep; 38(9):1173-81. PubMed ID: 25025451
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A state-wide population-based program for detection of lynch syndrome based upon immunohistochemical and molecular testing of colorectal tumours.
    Schofield L; Grieu F; Goldblatt J; Amanuel B; Iacopetta B
    Fam Cancer; 2012 Mar; 11(1):1-6. PubMed ID: 22120844
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.